Canadian CANNAINVESTOR Magazine July / August 2018 | Page 82

TSXV: GTEC

CCIM: There are many Licensed Producers in the Canadian market. Besides being “organic” How else do you plan on competing (e.g. price, quality)?

GTEC: Superior quality and product innovation will be key success drivers for the company. GreenTec’s product portfolio will be designed to target distinct consumer segments within the premium craft cannabis market. Superior genetics, hand-trimming, curing and grading all play a key role in delivering superior products. This will be augmented by marketing efforts that highlight the unique qualities of our products in a manner that resonates with consumers.

CCIM: Your flagship holding, GreenTec Bio-Pharmaceuticals, has three locations. What is the significance of GreenTec that makes it the flagship subsidiary?

GTEC: GreenTec Bio-Pharmaceuticals was our first acquisition (in July 2017). Originally, we planned for this to be our largest craft cannabis cultivation facility. It will be our most technologically advanced facility. However, our recent F-20 joint venture is a larger scale facility than GreenTec Bio.

82

GTEC Holdings Ltd. (TSXV: GTEC; OTC:GGTTF)

Mike Blady, Co-founder & VP, Investor Relations

CannaInvestor Magazine Canada

Louis Kyron, CPA, CGA & Derwin Wallace, CEO (CCIM)